Publication date: Jun 12, 2025
Early results suggest drugs targeting lipid peroxidation and ferroptosis or additional receptor tyrosine kinases could be part of an effective combination drug strategy. The researchers are also examining possible combination therapies that would enhance the anti-tumor effects of EGFR inhibition. NF1 mutations were found in 40% of these cases.
| Concepts | Keywords |
|---|---|
| Cancers | Drugs |
| Immunotherapies | Effective |
| Latest | Egfr |
| Overexpression | Growth |
| Professor | Inhibitor |
| Inhibitors | |
| Melanoma | |
| Mutant | |
| Mutations | |
| Nf1 | |
| Nyu | |
| Team | |
| Treatment | |
| Tumor | |
| Tumors |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | Cancer |
| drug | DRUGBANK | L-Tyrosine |
| pathway | KEGG | Ferroptosis |
| drug | DRUGBANK | Erlotinib |
| drug | DRUGBANK | Gefitinib |
| drug | DRUGBANK | Rasagiline |
| drug | DRUGBANK | Afatinib |
| drug | DRUGBANK | Cetuximab |
| disease | MESH | colorectal cancers |
(Visited 2 times, 1 visits today)